Pioneering non-invasive diagnostics through breath analysis and volatile organic compound research — bringing early cancer detection closer to clinical reality.
Our aim is to develop a single breath test to diagnose five major gastrointestinal cancers: oesophageal, gastric, pancreatic, liver and colorectal.
Analysing VOCs in exhaled breath as biomarkers for early-stage disease detection across multiple cancer types.
Profiling exhaleed VOC signatures using Thermal Desorption - Gas Chromatography - Time of Flight - Mass Spectrometry
The bespoke ML platform processes GC-MS breath data using molecular network analysis.
Large-scale multicentre trials across NHS trusts, 99% of patients find breath testing easy or very easy.
A novel breath test pathway designed to streamline suspected cancer referrals, minimise unnecessary invasive procedures and alleviate both the financial and operational strain on the NHS.
Biomarkers owned by Imperial College London. Over ten patents filed worldwide.